Jiangsu Micromedmark Biotech Co., Ltd.

Micromedmark Biotech Co., Ltd.

Jiangsu Mingma Biotech Co., Ltd.

Chinese Academy of Sciences

Bluestar (beijing) Chemical Machinery Co., Ltd.

Nanjing University

Junfeng Zhang

Ke Zeng

Chenyu Zhang

Haijin Li

Yi Ba

Xi Chen

Xiaolong Li

Jin Wang

Jiangning Chen

Hongjie Zhang

Yuan Yin

Lei Dong

Hongwei Liang

Dongsheng Sun

Chengkun He

Xuehua Wu

Zhengping Zhang

Chengyu Zhang

Xing Cai

Chunliang Tian

Xiuming Liu

Jianzhong Kang

Lirui Zhang

Zhen Huang

Xiaofeng Qiao

Junzhi Zhang

Weihong Wang

Lifang Wang

A configuration control method for an electronic mechanical brake-by-wire system is Provided. The control method includes: acquiring a first actual output torque measured by the first torque sensor and a second actual output torque measured by the second torque sensor; if a received signal is a brake loading signal, separately comparing a first difference with an initial torque difference and a maximum torque difference when a motor fails to obtain a comparison result, where the first difference is an absolute value of a difference between the first actual output torque and the second actual output torque; and controlling the first motor and the second motor according to the comparison result to complete brake loading by means of the brake actuator. Also provided is a configuration control system for an electronic mechanical brake-by-wire system. The control method and the control system can achieve synchronous and precise control of a brake force.

Configuration control method and control system for electronic mechanical brake-by-wire system

Provided are non-small cell lung cancer markers and the use thereof in diagnosing and monitoring diseases in vitro. The non-small cell lung cancer markers include at least one of 26 selected detectable mature microRNAs existing stably in human serum or plasma. Also provided are probe combinations, a kit and a biochip for detecting the non-small cell lung cancer markers. The invention further provides a method for detecting the said lung cancer markers. The method in the present invention enables extensive detection spectrum, high sensitivity, low cost, convenient sample taking and preservation. The method can be applied in the general survey of disease, solves problems of low specificity and sensitivity encountered with previous single markers, and increases significantly the clinical detection rate of diseases. The methods provide an effective means for diagnosing diseases at an early stage.

Serum or plasma microRNA as biomarkers for non-small cell lung cancer

Provided are a new precursor miRNA and the applications in tumor therapy thereof. The precursor miRNA, from 5'- to 3&#x2032;-end thereof, has the structure represented by formula (I). B1 is an anti-miRNA and/or siRNA to be expressed; B2 is a sequence substantially or completely complementary to B1, and B2 is not complementary to C; C is a sequence with stem-loop structure; A1 and A2 are independently hydrogen or optionally a RNA sequence consisting of 4 to 5 bases. The precursor miRNA can be processed to form an anti-miRNA and/or siRNA in hosts. 

Precursor miRNA and applications in tumor therapy thereof

Provided is a use of miRNA-214 inhibitor in inhibiting regulatory T cells (Treg cells). The microRNA-214 (miRNA-214) can promote Treg cells, and can assist tumors in immune escape. The experiments demonstrates that the inhibition of miRNA-214 can inhibit the growth of Treg cells, thus inhibiting the growth of tumors. Therefore, miRNA-214 can be used for developing an anti-tumour drug or a drug inhibiting immune response hyperactivity.

Use of miRNA-214 inhibitor in inhibiting regulatory cells

Disclosed is an ion exchange membrane electrolytic cell, comprising an anode chamber and a cathode chamber; a gas-liquid separation chamber is arranged in the anode chamber and/or the cathode chamber; the gas-liquid separation chamber is partially located inside the anode chamber and/or the cathode chamber; a first portion of the gas-liquid separation chamber, which is configured to accommodate liquid, is arranged inside the anode chamber and/or the cathode chamber; and a second portion of the gas-liquid separation chamber, which is configured to accommodate gas, is disposed outside of the anode chamber and/or the cathode chamber. The ion exchange membrane electrolytic cell is provided with the gas-liquid separation chamber partially located inside the anode chamber and/or the cathode chamber, thereby improving the yield of the ion exchange membrane electrolytic cell. On the other hand, the products of electrolysis can be drained rapidly.

Ion exchange membrane electrolytic cell

This invention provides a combination of microRNAs for evaluating the physiological and/or pathological condition of a subject, wherein the combination comprises all detectable microRNAs stably existing in the serum/plasma of a subject; and a method for evaluating the physiological and/or pathological condition of a subject, wherein the method includes determining all detectable microRNAs stably existing in the serum/plasma of a subject; and a kit for evaluating the physiological and/or pathological condition of a subject, wherein the kit contains the tools for determining all detectable microRNAs that stably existing in the serum/plasma of a subject; and a biochip for evaluating the physiological and/or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum/plasma of a subject. The aforementioned combination, method, kit and biochip can be used for diagnosis as well as differentially diagnosis of diseases including various tumors; various acute/chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system, prediction of complications occurrence and malignant diseases relapse, evaluation of therapeutic effects, screening of pharmaceutical active ingredients, assessment of drug efficacy as well as forensic authentication and prohibited drug inspection and the like, possessing a number of advantages such as extensive detection spectrum, high sensitivity, low cost, convenience for sampling, ease for sample preservation, etc. The said method can be widely used in work related to general survey of diseases and so on, improve the low-specificity and low-sensitivity caused by individual differences which single markers are difficult to overcome, significantly increasing the clinical detection rate of diseases, all of which make it become an effective means for diagnosing diseases in an early phase.

Serum/plasma MicroRNAs and uses thereof

MicroRNAs are provided for evaluating the physiological and/or pathological condition of a subject; and a kit thereof is provided for evaluating the physiological and/or pathological condition of a subject, wherein the kit contains the tools for determining all detectable microRNAs that stably existing in the serum/plasma of a subject; and a biochip for evaluating the physiological and/or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum/plasma of a subject. The aforementioned combination, method, kit and biochip can be used for diagnosis as well as differentially diagnosis of diseases including various tumors.

The present invention relates to a method for modulating miRNA content in living beings and the use thereof, whereof the miRNAs are delivered initiatively and selectively by microparticles/MVs/exosomes to the circulatory system and target cells/tissues to perform various functions. The invention provides a novel combination of molecules that mediates the inter-cellular communication: the miRNAs secreted by cells through cellular MVs. Meanwhile, the present invention also provides a method for preparing cellular MVs entrapping certain miRNAs, and, according to the regulation and modification of gene expression in cells and tissues with the miRNA-entrapping cellular MVs, provides a novel method for modulating miRNA content in living beings, which is effective and adoptable to all cell types.

Method for modulating microRNA content in living beings and the use thereof

An isolated plant-functional microRNA or an extract containing said plant-functional microRNA, a preparation method therefor, and an application thereof are provided. The plant-functional microRNA originates from the endogenous microRNA of a plant, is present in a water-soluble and/or fat-soluble extract of said plant, and is capable of regulating non-plant target-genes.

Extraction, preparation, and application of plant micro-ribonucleic acid

This invention provides markers, methods, biochips and kits for milk quality detection. The present invention particularly provides a method for milk quality detection by means of detecting the particular microRNAs in milk, so as to establish the standard of raw milk content.

Markers, biochips and kits for milk quality detection

The present invention provides non-small cell lung cancer markers and the use thereof in diagnosing and monitoring diseases in vitro. The non-small cell lung cancer markers include at least one of the 26 selected detectable mature microRNAs existing stably in human serum or plasma. The invention also provides probe combinations, a kit and biochip for detecting the non-small cell lung cancer markers. The invention further provides a method for detecting the said lung cancer markers. The method in the present invention enables extensive detection spectrum, high sensitivity, low cost, convenient sample taking and preservation. The method can be applied in the general survey of disease, solves problems of the low specificity and sensitivity encountered with previous single markers, and increases significantly the clinical detection rate of diseases; it forms an effective means for diagnosing diseases at an early stage.

Growing community of inventors

Beijing, China

Junfeng Zhang